Trials / Terminated
TerminatedNCT02161185
A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- UCB Biopharma S.P.R.L. · Industry
- Sex
- All
- Age
- 12 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to examine the long-term safety and tolerability of USL261 in the treatment of seizure clusters.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | USL261 | 5 mg, intranasal dose for seizure cluster, may repeat as indicated by protocol |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2015-05-01
- Completion
- 2015-05-01
- First posted
- 2014-06-11
- Last updated
- 2019-10-10
- Results posted
- 2019-01-14
Locations
16 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02161185. Inclusion in this directory is not an endorsement.